Mesoblast Ltd (MESO): Rega marang dodolan

Mesoblast Limited (MESO) is seeking strategic partners among industry behemoths for the global distribution of its drugs. After evaluating the price-to-sales trend on GURU.Markets, we find that the current status is 14.10. High R&D expenditures and stringent FDA oversight create significant barriers. Market exclusivity is driven by the high cost of clinical trials and unique patent protection for biomanufacturing.

mesoblast.com - Rasio rega marang pendapatan MESO (periode 04.07.2022 - 13.11.2026)

Rincian metrik lan analitis perusahaan Mesoblast Corp (MESO)

- rega lan prakiraan konsensus rega:

Bagan bursa mesoblast.com|MESO - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar Mesoblast Corp|MESO - Nilai Perusahaan

- data nilai buku modal saham:

Aset Bersih saben Siji Saham Mesoblast|MESO - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku mesoblast.com|MESO - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Total Utang marang Modal Mesoblast Limited|MESO - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal Mesoblast Pharma|MESO - Gunggung utang perusahaan|Utang marang modal buku Mesoblast Corp|MESO - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Mesoblast|Likuiditas cepet mesoblast.com

- rincian asil keuangan lan kelipatan valuasi:

MESO - Bathi resik|Prakiraan bathi perusahaan Mesoblast Limited|MESO - Rasio rega marang bathi|Prakiraan rega marang bathi Mesoblast Ltd|MESO - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Mesoblast Corp|MESO - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan Mesoblast|MESO - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan mesoblast.com|MESO - Wutah bathi ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Mesoblast Limited

- data total pendapatan lan volume dodolan:

MESO - Pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan mesoblast.com|MESO - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Mesoblast Corp

Ringkesan analitik perusahaan:mesoblast.com

Mesoblast Limited is accumulating significant scientific capital in the field of regenerative therapy and stem cells, which defines the specifics of its valuation. This indicator compares market capitalization with sales volume, allowing the current price-to-sales ratio to determine the extent of the premium paid for future R&D success and assess the probability of quotes returning to historical average values.

Karo sapa Mesoblast Limited saingan

Koefisien rega marang pendapatan lineagecell.com|Rasio rega marang pendapatan Surrozen SRZN|Cryo-Cell (CCEL) - Rega marang dodolan|FibroBiologics Corp - Multiplikator P/S|LGVN: Rasio rega marang pendapatan|biorestorative.com (BRTX) - Rasio rega marang pendapatan|CELZ (Creative Medical Technology Holdings) - Rasio rega marang pendapatan